Vol 72, No 1 (2021)
Clinical vignette
Published online: 2021-01-11

open access

Page views 914
Article views/downloads 795
Get Citation

Connect on Social Media

Connect on Social Media

Adjuvant therapy in type 1 diabetes mellitus

Edyta Cichocka1, Anna Maj-Podsiadło, Janusz Gumprecht1
Pubmed: 33619718
Endokrynol Pol 2021;72(1):87-88.

Abstract

Not required for Clinical Vignette.

Article available in PDF format

View PDF Download PDF file

References

  1. Polsky S, Ellis SL. Obesity, insulin resistance, and type 1 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 2015; 22(4): 277–282.
  2. Al Khalifah RA, Alnhdi A, Alghar H, et al. The effect of adding metformin to insulin therapy for type 1 diabetes mellitus children: A systematic review and meta-analysis. Pediatr Diabetes. 2017; 18(7): 664–673.
  3. Libman IM, Miller KM, DiMeglio LA, et al. T1D Exchange Clinic Network Metformin RCT Study Group. Effect of Metformin Added to Insulin on Glycemic Control Among Overweight/Obese Adolescents With Type 1 Diabetes: A Randomized Clinical Trial. JAMA. 2015; 314(21): 2241–2250.
  4. Maj-Podsiadło A, Cichocka E, Gumprecht J. SGLT-2 inhibitors as adjunctive to insulin therapy in type 1 diabetes. Clin Diabetol. 2020; 9(3): 189–192.
  5. Huang Y, Jiang Z, Wei Y. Short- and medium-term efficacy of sodium glucose cotransporter 2 (SGLT-2) inhibitors for the treatment of type 1 diabetes: systematic review and meta-analysis. Endokrynol Pol. 2020; 71(4): 325–333.
  6. Mathieu C, Zinman B, Hemmingsson JU, et al. ADJUNCT ONE Investigators. Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial. Diabetes Care. 2016; 39(10): 1702–1710.